

Luton & Dunstable University Hospital
Bedfordshire Hospitals NHS Foundation Trust
Lewsey Road
Luton
LU4 0DZ

Bedford Hospital
Bedfordshire Hospitals NHS Foundation Trust
Kempston Road
Bedford
MK42 9DJ

01/12/2020

Dear Requester,

Thank you for your Freedom of Information request which was received within the Trust.

In accordance with S.1 (1) (a) of the Freedom of Information Act 2000 (FOIA), I can confirm that we hold the information relevant to your request. FOI 2020

Response from Luton and Dunstable University Hospital

I am researching the incidence and treatment of Renal Cancer (RCC) and Colorectal Cancer (CRC). Could you please answer the following questions for patients treated by your trust?

1. Within your health trust, how many patients have been treated in the past 3 months with the following agents for renal cell carcinoma?

- Sunitinib
- Avelumab + Axitinib
- Axinitib
- Cabozantinib
- Everolimus
- Lenvantinib + Everolimus
- Nivolumab
- Nivolumab + Ipilimumab
- Pazopanib
- Pembrolizumab + Axitinib
- Sunitinib
- Temsirolimus
- Tivozanib
- Other

Luton and Dunstable Hospital does not provide anti-cancer treatments to patients with renal cell carcinoma.

2. Does your trust participate in any ongoing clinical trials for the treatment of renal cell carcinoma? If so, can you please provide the name of each trial along with the number of patients taking part?

In answer to question 2 of the FOI request: There are no renal cell carcinoma trials being run at the Luton and Dunstable University Hospital, neither open to recruitment nor in follow up so we have no participants.

3. Within your health trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?

- Afibercept: **0**
- Bevacizumab: **0**
- Capecitabine: **2**
- CAPIRI: **0**
- CAPOX: **9**
- Cetuximab in combination with FOLFIRI: **1**
- Cetuximab in combination with FOLFOX: **0**
- Cetuximab not in combination with FOLFIRI or FOLFOX: **0**
- Irinotecan: **2**
- FOLFIRI: **13**
- FOLFOX: **9**
- Oxaliplatin: **0**
- Panitumumab in combination with FOLFIRI: **0**
- Panitumumab in combination with FOLFOX: **0**
- Panitumumab not in combination with FOLFIRI or FOLFOX: **0**
- Nivolumab: **0**
- Raltitrexed: **1 (in combination with oxaliplatin)**
- Ramucirumab: **0**
- Regorafenib: **0**
- Sorafenib: **0**
- 5FU only: **1**
- Tegafur Uracil + 5FU: **0**
- Trifluridine–tipiracil: **0**
- XELOX: **(see CAPOX)**
- Other: **0**

Response from Bedford Hospital

1. Within your health trust, how many patients have been treated in the past 3 months with the following agents for renal cell carcinoma?

- Sunitinib = **0**
- Avelumab + Axitinib = **0**
- Axinitib = **0**
- Cabozantinib = **0**
- Everolimus = **0**
- Lenvantinib + Everolimus = **0**
- Nivolumab = **0**
- Nivolumab + Ipilimumab = **0**
- Pazopanib = **0**
- Pembrolizumab + Axitinib = **0**
- Sunitinib = **0**
- Temsirolimus = **0**
- Tivozanib = **0**
- Other = **0**

2. Does your trust participate in any ongoing clinical trials for the treatment of renal cell carcinoma? If so, can you please provide the name of each trial along with the number of patients taking part? = **No**

3. Within your health trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?

- Afibercept = 0
- Bevacizumab = 1
- Capecitabine = 5
- CAPIRI = 6
- CAPOX = 0
- Cetuximab in combination with FOLFIRI = 8
- Cetuximab in combination with FOLFOX = 0
- Cetuximab not in combination with FOLFIRI or FOLFOX = 0
- Irinotecan = 0
- FOLFIRI = 3
- FOLFOX = 7
- Oxaliplatin = 0
- Panitumumab in combination with FOLFIRI = 0
- Panitumumab in combination with FOLFOX = 1
- Panitumumab not in combination with FOLFIRI or FOLFOX = 0
- Nivolumab = 0
- Raltitrexed = 1
- Ramucirumab = 0
- Regorafenib = 0
- Sorafenib = 0
- 5FU only = 0
- Tegafur Uracil + 5FU = 0
- Trifluridine–tipiracil = 4
- XELOX = XELOX is the same regimen as CAPOX
- Other = N/A

This information is provided for your personal use and is the property of Bedfordshire Hospitals NHS Trust and subject to any existing Intellectual Property and Database Rights. Any commercial application or use of this information may be subject to the provisions of the Re-use of Public Sector Information Regulations 2015 (RPSI). This means that if you wish to re-use the information provided for commercial purposes for any reason you must ask the Trust for permission to do so.

Please note that the Trust has a formal internal review and complaints process which is managed by the Information Governance Manager/Data Protection Officer. Should you have any concerns with our response, you can make a formal request for an internal review. Requests *for internal review* should be submitted within three months of the date of receipt of the response to your original letter, and should be addressed to:

Luton & Dunstable University Hospital
Bedfordshire Hospitals NHS Foundation Trust
Lewsey Road
Luton
LU4 0DZ

Bedford Hospital
Bedfordshire Hospitals NHS Foundation Trust
Kempston Road
Bedford
MK42 9DJ

Or by emailing bhn-tr.foibedfordshirehospitals@nhs.net. This option is available to you for up to three calendar months from the date your response was issued.

If you are not satisfied with the Trust review under the Freedom of Information Act 2000 you may apply directly to the Information Commissioners Officer (ICO) for a review of your appeal decision. The ICO can be contacted at: ICO, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF
www.ico.org.uk

Yours sincerely,

IG/FOI Coordinator

Bedford Hospital, Kempston, Bedford
MK42 9DJ

Luton & Dunstable Hospital
Lewsey Road, Luton
LU4 0DZ